Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2017 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia

Multi-center, international trial targets significant unmet need for which no treatments are approved Approximately 500 patients to be enrolled at 60 clinical sites in U.S. and Europe WALTHAM,...
December 11, 2017 16:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Names Richard Russell President

WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
December 11, 2017 08:15 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors

WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
December 06, 2017 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder

WALTHAM, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
November 08, 2017 09:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Present at Jefferies 2017 London Healthcare Conference on November 15, 2017

WALTHAM, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
November 06, 2017 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Third Quarter 2017 Financial Results and Business Updates

WALTHAM, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
October 31, 2017 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product Strategy

WALTHAM, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
October 30, 2017 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Report Third Quarter 2017 Financial Results and Business Updates on November 6, 2017

WALTHAM, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
September 11, 2017 08:30 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and Development

WALTHAM, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
September 05, 2017 08:00 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder

WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...